By

Admin
Emma Holden was devastated when she learned she had multiple myeloma. The 31-year-old, who lives in South Canterbury, was diagnosed with the form of blood cancer in June last year. When she first was told of the cancer she hadn’t heard of it before. Multiple myeloma causes cancer cells to accumulate in bone marrow, where they...
Continue Reading
Pharmac will ease restrictions on at least nine cancer drugs, including keytruda for the treatment of advanced melanoma, to reduce hospital visits and cut the risk of highly vulnerable patients catching Covid-19. One senior oncologist has praised the drug buying agency’s swift response, although patient advocates say cancer sufferers will need much more help during...
Continue Reading
New Zealanders living with the incurable blood cancer, multiple myeloma, are set to gain access to a new treatment option following the decision by PHARMAC to subsidise REVLIMID® (lenalidomide) for maintenance treatment from Wednesday April 1, 2020 REVLIMID® (lenalidomide) represents New Zealand’s first and only maintenance treatment specifically indicated and reimbursed for those with newly...
Continue Reading
Researchers at the VU University Medical Center in the Netherlands have tested a new drug in patient samples and mice with multiple myeloma and discovered that it was effective even in advanced disease – a point when many patients currently run out of options. These promising results could pave the way for the new drug...
Continue Reading
COVID-19, short for coronavirus disease 2019, is an infection caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is a newly identified pathogen that has not previously been seen in humans and is highly contagious. Though it belongs to the same category of viruses as SARS coronavirus (SARS-CoV) and influenza viruses, SARS-CoV-2 is a...
Continue Reading
ROTTERDAM, Netherlands and SAN DIEGO, March 17, 2020 /PRNewswire/ — SkylineDx shares research showing that multiple myeloma (blood cancer) patients with a high risk or aggressive course of the disease are unlikely to benefit from current treatment approaches, including lenalidomide mono-therapy for maintenance when compared to observation only. The Institute of Cancer Research (ICR) in London (UK), derived these results from the...
Continue Reading
With rising community concern about the novel coronavirus or COVID-19, Myeloma Australia would like to provide the following information sheet detailing risks and preventative measures specific to the myeloma population. The coronavirus family are known to cause Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). COVID-19 is the name that has been...
Continue Reading
Highlights include: Daratumumab + standard care in newly diagnosed MM OS with daratumumab + bortezomib/melphalan/prednisone in newly diagnosed MM Frontline treatment of elderly non transplant-eligible MM patients using cyclophosphamide, bortezomib, dexamethasone Download here: Multiple Myeloma Research Review Issue 33
Continue Reading
A new CAR T-cell therapy for people with multiple myeloma has been successfully created and tested in cell-based experiments and a mouse model, a study reported. This therapy targets a protein called CD229, produced on the surface of both myeloma cells and cancer stem cells — the source of treatment-resistant cells that may lead to disease recurrence — potentially...
Continue Reading
Immunoglobulin light chain amyloidosis (AL amyloidosis) involves deposition of abnormally folded light chains into a wide range of tissues causing organ dysfunction, including in the heart and kidney. Daratumumab, a CD38-targeted antibody, has recently demonstrated efficacy in producing hematologic responses in previously treated disease. However, data on survival outcomes and organ responses to daratumumab are...
Continue Reading
1 2 3 21

Floor 7, 90 The Terrace
Wellington Central
New Zealand